Overall Survival – Page 2

AstraZeneca’s Imfinzi Demonstrates Significant Survival Benefits in Muscle-Invasive Bladder Cancer

7 months ago talkbio0Tagged AstraZeneca, durvalumab, Event-Free Survival, Imfinzi, MIBC, muscle-invasive bladder cancer, NIAGARA, Overall Survival, perioperative, Phase 3 Clinical Trials

AstraZeneca, Imfinzi (durvalumab), Muscle-Invasive Bladder Cancer (MIBC), Perioperative Treatment, Event-Free Survival (EFS), Overall Survival (OS), NIAGARA Phase III Trial

ESMO 2023: Merck’s Welireg Demonstrates Sustained PFS Benefit in Advanced Renal Cell Carcinoma, Despite Ongoing OS Concerns

7 months ago talkbio0Tagged belzutifan, Co., ESMO, LITESPARK-005 trial, Overall Survival, Progression-Free Survival, Renal Cell Carcinoma, Welireg

Merck & Co., Welireg (belzutifan), ESMO 2023, Advanced Renal Cell Carcinoma (RCC), Progression-Free Survival (PFS), Overall Survival (OS), LITESPARK-005 trial

KEYTRUDA (Pembrolizumab) Plus Chemoradiotherapy Reduces Mortality Risk by 33% in High-Risk Locally Advanced Cervical Cancer

7 months ago talkbio0Tagged Chemoradiotherapy, Congress, Congress (U.S. Legislature), high-risk, Keytruda, Locally, Malignant tumor of cervix, Overall Survival, pembrolizumab

KEYTRUDA (pembrolizumab), Chemoradiotherapy (CRT), High-risk locally advanced cervical cancer, Overall survival (OS), European Society for Medical Oncology (ESMO) Congress 2024

AstraZeneca and Daiichi Sankyo’s Dato-DXd Fails to Meet Overall Survival Goal in NSCLC Study, FDA Decision Looms

8 months ago talkbio0Tagged AstraZeneca, Clinical Research, Daiichi, Dato-DXd, Datopotamab deruxtecan, Decision, Non-Small Cell Lung Carcinoma, Overall Survival, Sankyo, TROPION-Lung01, United States Food and Drug Administration

AstraZeneca, Daiichi Sankyo, Dato-DXd (datopotamab deruxtecan), Non-small cell lung cancer (NSCLC), Overall survival (OS), FDA decision, TROPION-Lung01 study

FDA Approves Broader Label for GSK’s Jemperli in First-Line Endometrial Cancer

9 months ago talkbio0Tagged dostarlimab-gxly, Jemperli, Malignant neoplasm of endometrium, Mismatch Repair, Overall Survival, paclitaxel, Pharmacotherapy, proficient, Progression-Free Survival, SmithKline Beecham, Stable status, United States Food and Drug Administration

FDA, GSK, Jemperli, dostarlimab-gxly, endometrial cancer, chemotherapy, carboplatin, paclitaxel, mismatch repair proficient, microsatellite stable, overall survival, progression-free survival

AstraZeneca’s Truqap Combo Fails to Improve Survival in Phase III Triple-Negative Breast Cancer Trial

10 months ago talkbio0Tagged AKT1 protein, human, AstraZeneca, CAPItello-290, capivasertib, Overall Survival, paclitaxel, Phase 3 Clinical Trials, PIK3CA gene, PTEN gene, Triple Negative Breast Neoplasms, Truqap

AstraZeneca, Truqap, capivasertib, Phase III trial, triple-negative breast cancer, CAPItello-290, paclitaxel, overall survival, PIK3CA, AKT1, PTEN

Gilead’s Trodelvy Fails to Meet Primary Endpoint in Confirmatory Trial for Urothelial Cancer

11 months ago talkbio0Tagged Antibody-Drug Conjugates, Approved, Clinical Trials, Gilead Sciences, Neoplasms, Overall Survival, Trodelvy, TROPiCS-04 study, United States Food and Drug Administration, urothelial cancer

Gilead Sciences, Trodelvy, urothelial cancer, TROPiCS-04 study, overall survival, antibody-drug conjugate, oncology, clinical trials, FDA approval

AstraZeneca’s Imfinzi Demonstrates Survival Benefit in Limited-Stage Small Cell Lung Cancer Study

1 year ago talkbio0Tagged ADRIATIC, AstraZeneca, durvalumab, Imfinzi, Immunotherapy, Limited-stage SCLC, Overall Survival, Phase 3 Clinical Trials, Progression-Free Survival, Small cell carcinoma of lung

AstraZeneca, Imfinzi (durvalumab), Small Cell Lung Cancer (SCLC), Limited-stage SCLC, ADRIATIC Phase III study, Overall Survival (OS), Progression-Free Survival (PFS), Immunotherapy

FDA Greenlights Opdivo Combination Therapy for First-Line Bladder Cancer Treatment

1 year ago talkbio0Tagged cisplatin, Combined, Opdivo, Overall Survival

Overall Survival, Combined, cisplatin, Opdivo